Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor ==Also known as== *'''Code name:''' TGR-1202 Category:...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor | Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Follicular lymphoma]] | ||
| + | *[[Marginal zone lymphoma]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2/5/2021: Approved for adult patients with relapsed or refractory [[marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one prior [[Regimen_classes#Anti-CD20-based_regimen|anti-CD20-based regimen]]. | ||
| + | *2/5/2021: Approved for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] who have received at least three prior lines of systemic therapy. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' TGR-1202 | *'''Code name:''' TGR-1202 | ||
| + | *'''Brand name:''' Ukoniq | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 10: | Line 19: | ||
[[Category:PI3K delta inhibitors]] | [[Category:PI3K delta inhibitors]] | ||
[[Category:CK1 epsilon inhibitors]] | [[Category:CK1 epsilon inhibitors]] | ||
| − | |||
| − | [[Category: | + | [[Category:Follicular lymphoma medications]] |
| + | [[Category:Marginal zone lymphoma medications]] | ||
| + | [[Category:FDA approved in 2021]] | ||
Revision as of 13:42, 6 February 2021
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2/5/2021: Approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
- 2/5/2021: Approved for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq